GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Research & Development

VGI Health Technology (XNEC:VTL) Research & Development : A$ Mil (TTM As of . 20)


View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. VGI Health Technology's Research & Development for the six months ended in . 20 was A$0.00 Mil. VGI Health Technology does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in . 20.


VGI Health Technology Research & Development Historical Data

The historical data trend for VGI Health Technology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Research & Development Chart

VGI Health Technology Annual Data
Trend
Research & Development

VGI Health Technology Semi-Annual Data
Research & Development

VGI Health Technology Research & Development Calculation

This is the expense the company spent on research and development.


VGI Health Technology  (XNEC:VTL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


VGI Health Technology Research & Development Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


VGI Health Technology (XNEC:VTL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003
VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines